FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy

Chronic Hepatitis C Virus Infection Clinical Trial

Official title:

FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00606528
• Other study ID #: 07-0841-T
• Status: Completed
• Phase: N/A
• First received: January 21, 2008
• Last updated: July 24, 2013
• Start date: February 2008

Study information

• Verified date: July 2013
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Observational

Clinical Trial Summary

The main objective of this study is to assess whether a recently-developed bioassay for the protein FGL2 can be used to predict the progression and/or response to treatment of Hepatitis C Virus disease in patients with chronic HCV infection. The hypothesis is that increased levels of FGL2 and increased numbers of T regulatory cells are associated with a failure to respond to treatment.

Description:

The current therapy for chronic Hepatitis C Virus infection leads to a sustained viral response in only 50% of treated patients. Evidence suggests that a poor response to treatment may be the result of a dysfunction of immunoregulatory mediators including T regulatory cells (Tregs) which secrete FGL2. The aim of this study is to test whether serum FGL2 levels can serve as a biomarker for clinical progress and treatment response in patients undergoing anti-viral therapy for chronic HCV infection.

This study will measure the blood Treg and FGL2 levels of patients with chronic Hepatitis C as they undergo antiviral therapy and will compare those levels to their pre-treatment and post-treatment levels. Treg and FGL2 expression levels will also be measured in patients' liver biopsy tissue when available.

Additionally, this study will examine the main form(s)of Fc Receptor expressed in these patients. The Fc receptor is the hypothesized binding partner of FGL2, and the form expressed in a given patient may determine the downstream effects of FGL2's binding. These data along with clinical, biochemical and virological data will be used to determine whether there is a correlation between FGL2 levels and disease outcome and/or treatment response.

The study will also recruit a group of normal healthy volunteers to give blood samples on two occasions so that the baseline range of FGL2 levels in healthy individuals can be established for comparison.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. primary completion date: July 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

HCV patient population

Inclusion Criteria:

• able to give written consent

• 18-70 yrs of age, both genders

• willing to use adequate contraception

• diagnosis of chronic HCV infection (of any genotype) based on 2 positive serology tests

• availability of pre- and post-treatment viral load data

• naive to antiviral treatment

• availability of pre-treatment liver biopsy

Exclusion Criteria:

• less than 18 yrs, greater than 70 yrs of age

• pregnancy

• HBV, HDV, or HIV co-infection

• any history of active alcohol or drug abuse

Volunteer Population (Control)

Inclusion Criteria:

• able and willing to provide written informed consent

• willing to provide a brief review of medical history

• 18-70 yrs of age, of either gender

Exclusion Criteria:

• less than 18, greater than 70 yrs of age

• any history of liver, renal, lung, hematological or coronary artery disease

• any history of active alcohol or drug abuse

• any previous diagnosis of HBV, HCV, HDV or HIV

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Chronic Hepatitis C Virus Infection
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic
• Infection
• Virus Diseases

Intervention

Other:
• No intervention
None. This is an observational study.

Locations

Country	Name	City	State
Canada	University Health Network	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

References & Publications (3)

Chan CW, Kay LS, Khadaroo RG, Chan MW, Lakatoo S, Young KJ, Zhang L, Gorczynski RM, Cattral M, Rotstein O, Levy GA. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J Immunol. 2003 Apr 15;170(8):4036-44. — View Citation

Liu H, Zhang L, Cybulsky M, Gorczynski R, Crookshank J, Manuel J, Grant D, Levy G. Identification of the receptor for FGL2 and implications for susceptibility to mouse hepatitis virus (MHV-3)-induced fulminant hepatitis. Adv Exp Med Biol. 2006;581:421-5. — View Citation

Shalev I, Liu H, Koscik C, Bartczak A, Javadi M, Wong KM, Maknojia A, He W, Liu MF, Diao J, Winter E, Manuel J, McCarthy D, Cattral M, Gommerman J, Clark DA, Phillips MJ, Gorczynski RR, Zhang L, Downey G, Grant D, Cybulsky MI, Levy G. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J Immunol. 2008 Jan 1;180(1):249-60. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	correlation between blood FGL2 levels and response to antiviral therapy		6 months after the end of treatment	No
Secondary	correlation between FGL2 levels and Treg percentage in blood and liver cells		all time points	No